Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin

Yoon Jae Lee, Yo Han Jang, Paul Kim, Yun Ha Lee, Young Jae Lee, Young Ho Byun, Kwang Hee Lee, Kyusik Kim, Baik Lin Seong

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

In our previous study, X-31ca-based H5N1 LAIVs, in particular, became more virulent in mice than the X-31ca MDV, possibly by the introduction of the surface antigens of highly pathogenic H5N1 influenza virus, implying that additional attenuation is needed in this cases to increase the safety level of the vaccine. In this report we suggest an approach to further increase the safety of LAIV through additional cold-adapted mutations in the hemagglutinin. The cold-adaptation of X-31 virus resulted in four amino acid mutations in the HA. We generated a panel of 7:1 reassortant viruses each carrying the hemagglutinins with individual single amino acid mutations. We examined their phenotypes and found a major attenuating mutation, N81K. This attenuation marker conferred additional temperature-sensitive and attenuation phenotype to the LAIV. Our data indicate that the cold-adapted mutation in the HA confers additional attenuation to the LAIV strain, without compromising its productivity and immune response.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalVirology
Volume491
DOIs
Publication statusPublished - 2016 Apr 1

Bibliographical note

Funding Information:
This study was supported by the grants from Korean Health Technology R&D Project , Ministry of Health and Welfare ( HI13C0826 ), and ICT and Future Planning, Ministry of Science , Republic of Korea ( NRF-2014M3A9E4064580 ). We are grateful to Dr. Manki Song at International Vaccine Institute, Seoul, Korea for providing A/Philippine/2/82 (H3N2) virus.

Publisher Copyright:
© 2016.

All Science Journal Classification (ASJC) codes

  • Virology

Fingerprint Dive into the research topics of 'Enhancement of the safety of live influenza vaccine by attenuating mutations from cold-adapted hemagglutinin'. Together they form a unique fingerprint.

Cite this